Should I buy or sell Aprea Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APRE shares. View APRE analyst ratings or view top-rated stocks .

What is Aprea Therapeutics' stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Aprea Therapeutics' shares. Their APRE share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 170.5% from the stock's current price. View analysts price targets for APRE or view top-rated stocks among Wall Street analysts .

How have APRE shares performed in 2024?

Aprea Therapeutics' stock was trading at $4.70 at the beginning of the year. Since then, APRE stock has increased by 21.9% and is now trading at $5.73. View the best growth stocks for 2024 here .

Are investors shorting Aprea Therapeutics?

Aprea Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 105,800 shares, a drop of 9.6% from the March 15th total of 117,100 shares. Based on an average trading volume of 34,600 shares, the days-to-cover ratio is currently 3.1 days. Approximately 2.4% of the company's shares are sold short. View Aprea Therapeutics' Short Interest .

When is Aprea Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our APRE earnings forecast .

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.33 million.

When did Aprea Therapeutics' stock split?

Aprea Therapeutics's stock reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV) , Brainstorm Cell Therapeutics (BCLI) , Biogen (BIIB) , Adaptimmune Therapeutics (ADAP) , Alector (ALEC) , Alkermes (ALKS) , Allogene Therapeutics (ALLO) , Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN) .

When did Aprea Therapeutics IPO?

Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:APRE

Aprea Therapeutics (APRE) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free APRE Stock Alerts

$5.73

-0.12 (-2.05%)

(As of 04/17/2024 ET)

Compare

Today's Range: $5.71
▼
$5.85
50-Day Range: $5.43
▼
$8.46
52-Week Range: $2.78
▼
$8.85

Volume: 2,289 shs
Average Volume: 31,186 shs
Market Capitalization: $31.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Get Aprea Therapeutics alerts:

Aprea Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 170.5% Upside
$15.50 Price Target
Short Interest: Healthy
2.35% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.07
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$71,952 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.38) to ($0.96) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.15 out of 5 stars

Medical Sector

321st out of 913 stocks

Pharmaceutical Preparations Industry

125th out of 396 stocks

3.5

Analyst's Opinion

Consensus Rating
Aprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Aprea Therapeutics has only been the subject of 2 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
2.35% of the float of Aprea Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aprea Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aprea Therapeutics has recently decreased by 9.65%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aprea Therapeutics does not currently pay a dividend.
Dividend Growth
Aprea Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for APRE.

1.7

News and Social Media Coverage

News Sentiment
Aprea Therapeutics has a news sentiment score of 0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Aprea Therapeutics this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for APRE on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aprea Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $71,952.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
20.90% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.19% of the stock of Aprea Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.38) to ($0.96) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aprea Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aprea Therapeutics is -1.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aprea Therapeutics has a P/B Ratio of 1.26. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Aprea Therapeutics Stock (NASDAQ:APRE)

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers. The company is also developing ATRN-1051, ATRN-354, and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

APRE Stock Price History

30 days | 90 days | 365 days | Advanced Chart

APRE Stock News Headlines

April 17, 2024 | americanbankingnews.com

Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

April 12, 2024 | markets.businessinsider.com

Aprea Therapeutics’ Promising Cancer Drug Candidate Warrants Buy Rating

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 10, 2024 | globenewswire.com

Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024

April 3, 2024 | msn.com

Aprea Therapeutics files to sell 4.39M shares of common stock for holders

March 28, 2024 | markets.businessinsider.com

Aprea Therapeutics: Strong Financials and Promising Clinical Pipeline Support Buy Rating

March 27, 2024 | markets.businessinsider.com

Buy Rating Affirmed: Aprea Therapeutics Poised for Growth with Strong Pipeline Momentum into 2024

March 26, 2024 | investorplace.com

APRE Stock Earnings: Aprea Therapeutics Misses EPS, Misses Revenue for Q4 2023

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 26, 2024 | globenewswire.com

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

March 20, 2024 | markets.businessinsider.com

Aprea Therapeutics: Strong Buy Rating on Robust Financials and Promising Drug Pipeline

March 18, 2024 | msn.com

Aprea Therapeutics Secures Up to $34 Million in Groundbreaking Financing Deal

March 16, 2024 | uk.investing.com

Aprea Therapeutics CFO buys $7,362 in company stock

March 16, 2024 | uk.investing.com

Aprea Therapeutics director buys $50k of company stock

March 14, 2024 | finance.yahoo.com

Karolinska Development’s portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

March 14, 2024 | globenewswire.com

Karolinska Development's portfolio company Aprea Therapeutics receives FDA IND approval and secures funding of USD 34 million

March 12, 2024 | markets.businessinsider.com

Aprea Therapeutics Secures Private Placement Financing Of Upto $34 Mln

March 11, 2024 | msn.com

Why Is Precision Oncology-Focused Aprea Therapeutics Stock Trading Higher On Monday?

March 11, 2024 | msn.com

Aprea Therapeutics announces private placement financing of up to $34M

March 11, 2024 | globenewswire.com

Aprea Therapeutics Announces Private Placement Financing of up to $34.0 Million

March 11, 2024 | globenewswire.com

Aprea Therapeutics Announces FDA Clearance of IND for APR-1051, its Next Generation WEE1 Kinase Inhibitor for Cyclin E Overexpressing Cancers

March 5, 2024 | globenewswire.com

Aprea Therapeutics Announces Acceptance of Abstracts at American Association of Cancer Research Annual Meeting 2024

February 23, 2024 | uk.investing.com

Aprea Therapeutics Inc (APRE)

February 7, 2024 | thestreet.com

Aprea Therapeutics Inc.

February 7, 2024 | msn.com

Aprea Therapeutics Updates Corporate Presentation Materials

February 6, 2024 | finance.yahoo.com

Aprea Therapeutics Announces Submission of IND Application for APR-1051, a Next Generation WEE1 Kinase Inhibitor

January 31, 2024 | msn.com

Biotechnology Center in Doylestown Seeks State Funding to Continue Support for Life Science Start-Ups

See More Headlines

Receive APRE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aprea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/26/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:APRE
CUSIP: N/A
CIK: 1781983
Web: www.aprea.com
Phone: 617-463-9385
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.50
High Stock Price Target: $20.00
Low Stock Price Target: $11.00
Potential Upside/Downside: +170.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.99)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,290,000.00
Net Margins: N/A
Pretax Margin: -2,450.60%
Return on Equity: -65.58%
Return on Assets: -52.37%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.13
Quick Ratio: 5.13

Sales & Book Value

Annual Sales: $580,000.00
Price / Sales: 53.64
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.54 per share
Price / Book: 1.26

Miscellaneous

Outstanding Shares: 5,430,000
Free Float: 4,295,000
Market Cap: $31.11 million
Optionable: No Data
Beta: 1.03

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Dr. Dansu Li Ph.D.
Head of Technology
Dr. Lars B. Abrahmsen Ph.D. (Age 67)
Senior VP & Chief Scientific Officer
Dr. Michel Afargan Ph.D.
Head of Pharmacology Development
Mr. Ze'ev Weiss B.Sc. (Age 62)
C.P.A., Chief Business Advisor
Ms. Andrea Epstein
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

APRE Stock Analysis - Frequently Asked Questions

Should I buy or sell Aprea Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aprea Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APRE shares.
View APRE analyst ratings or view top-rated stocks.
What is Aprea Therapeutics' stock price target for 2024?: 2 equities research analysts have issued 1 year target prices for Aprea Therapeutics' shares. Their APRE share price targets range from $11.00 to $20.00. On average, they expect the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 170.5% from the stock's current price.
View analysts price targets for APRE or view top-rated stocks among Wall Street analysts.
How have APRE shares performed in 2024?: Aprea Therapeutics' stock was trading at $4.70 at the beginning of the year. Since then, APRE stock has increased by 21.9% and is now trading at $5.73.
View the best growth stocks for 2024 here.
Are investors shorting Aprea Therapeutics?: Aprea Therapeutics saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 105,800 shares, a drop of 9.6% from the March 15th total of 117,100 shares. Based on an average trading volume of 34,600 shares, the days-to-cover ratio is currently 3.1 days. Approximately 2.4% of the company's shares are sold short.
View Aprea Therapeutics' Short Interest.
When is Aprea Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our APRE earnings forecast.
How were Aprea Therapeutics' earnings last quarter?: Aprea Therapeutics, Inc. (NASDAQ:APRE) posted its quarterly earnings results on Tuesday, March, 26th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.36. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.33 million.

When did Aprea Therapeutics' stock split?: Aprea Therapeutics's stock reverse split on the morning of Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.
What other stocks do shareholders of Aprea Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aprea Therapeutics investors own include AbbVie (ABBV), Brainstorm Cell Therapeutics (BCLI), Biogen (BIIB), Adaptimmune Therapeutics (ADAP), Alector (ALEC), Alkermes (ALKS), Allogene Therapeutics (ALLO), Alnylam Pharmaceuticals (ALNY) and Amgen (AMGN).
When did Aprea Therapeutics IPO?: Aprea Therapeutics (APRE) raised $52 million in an IPO on Thursday, October 3rd 2019. The company issued 5,000,000 shares at a price of $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets acted as the underwriters for the IPO.
How do I buy shares of Aprea Therapeutics?: Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:APRE) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aprea Therapeutics (APRE) Stock Price, News & Analysis

Aprea Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Aprea Therapeutics Stock (NASDAQ:APRE)

APRE Stock Price History

APRE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

APRE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™